Dr. Eileen J. Kennedy


Associate Professor

Office: Pharmacy South, Rm 342
Voice: 706-542-6497

Education

Research Associate, Chemistry and Chemical Biology, Harvard University 2009-2010

Postdoctoral Fellow, Chemistry and Chemical Biology , Harvard University 2006-2009

Ph.D. Chemistry and Biochemistry, University of California, San Diego 2005

M.S. Chemistry and Biochemistry, University of California, San Diego 2002

B.S. Biochemistry, University of Washington 1998

Research Interests

The protein kinase superfamily comprises one of the largest gene families encoded in the human genome.  A comprehensive understanding of kinase activity under normal and disease states is critical in order to identify targets for disease intervention.  However, studying kinase signaling is inherently challenging since there are more than 500 kinases in the human genome, and as a result, there is significant crosstalk among multiple kinases for phosphorylation targets.  Additionally, multiple isoforms exist for many kinases, thereby making it nearly impossible to address the question using genetic knockdowns/knockouts since other genes will compensate with altered expression levels.

To address this question, the Kennedy lab is developing novel chemical biology strategies to synthetically disrupt protein:protein interactions (PPIs) using chemically stabilized peptides.  This methodology allows for the development of investigative tools that can be applied to elegantly and selectively manipulate protein-protein interactions that are involved in signaling pathways within a cellular environment.  The long-term goal of the lab is to develop synthetic biologics that can be used to probe cell signaling events that are mediated by kinases.  By inhibiting specific protein:protein interactions within a cellular environment, cancer-related cell signaling events can be studied in a temporal manner and highlight new strategies for therapeutic intervention.  They are applying this strategy to study the AGC family of kinases as well as EGFR in breast and lung cancer models.

Grant Support

PI, R03, funded by the National Institutes of Health (National Cancer Institute), 2014-2016

PI, NCI Transition Career Development Award, funded by the National Institutes of Health (National Cancer Institute), 2011-2014

Of Note

GRC on Phosphorylation and G-Protein Mediated Signaling Networks, 2016
Invited Speaker, Biddeford, ME

5th International Meeting on Anchored cAMP Signaling, 2016
Invited Speaker, Zermatt, Switzerland

Experimental Biology 2016, 2016
Invited Speaker, San Diego, CA

13th Annual Biochemistry Retreat for Universitat Kassel, 2016
Invited Speaker, Wesendorf, Germany

ASBMB Special Symposia on Kinases and Pseudokinases, 2015
Invited Speaker, San Diego, CA

4th International Workshop on cAMP signaling, PKA and phosphodiesterases, 2015
Invited Speaker, Erciyes University, Kayseri, Turkey

American Peptide Society, 2015-2017
Elected Member, Nominating Committee

24th Annual American Peptide Symposium, 2015
Invited Session Chair, Orlando, FL

Drug Discovery and Therapy World Congress, 2015
Invited Speaker, Boston, MA

Universitat Kassel’s 12th Annual Biochemistry Retreat, 2015
Keynote Speaker, Wesendorf, Germany

8th International Meeting on Protein Kinases, 2014
Invited Speaker, Warsaw, Poland

EMBO’s Chemical Biology Conference, 2014
Invited Speaker, Heidelberg, Germany

6th International Peptide Symposium/23rd American Peptide Symposium Joint Conference, 2013
Invited Session Chair Waikoloa, HI

Office of the Provost, University of Georgia, 2013
Faculty Summer Research Support for Outstanding Scientists

4th International Meeting on Anchored cAMP Signaling Complexes, 2013
Invited Speaker, Denver, CO

Meeting on Cyclic Nucleotide Signaling in Malaria, 2013
Invited Speaker, CNRS, Paris, France

ASPET Session on “Building a Research Career in Pharmacology,” EB 2012
Invited Speaker, San Diego, CA

Gordon Research Conference in Bioorganic Chemistry, 2011
Discussion Leader for session entitled “Design and Engineering in Biological Systems”

Experimental Biology Sponsored by FASEB, 2011
FASEB MARC Program Travel Award Sponsored by ASPET, Washington, D.C.

Chemistry in Cancer Research: A Vital Partnership (AACR-ACS Joint Conference), 2009
Scholar-In-Training Award, New Orleans, LA

American Cancer Society Fellow (ACS), 2006-2009
Postdoctoral Fellowship

Chemistry in Cancer Research: A Vital Partnership (AACR-ACS Joint Conference), 2007
Scholar-In-Training Award, Awarded by Abbott Laboratories, San Diego, CA

American Heart Association Fellow (AHA), 2003-2005
Predoctoral Fellowship

Selected Publications

Bavencoffe A, Li Y, Wu Z, Yang Q, Kennedy EJ, Walters ET and Dessauer CW. (2016) “Persistent pain-related activity in primary nociceptors after spinal cord injury is maintained by scaffolded adenylyl cyclase and Protein Kinase A.” Neuroscience, 36: 1660-8, DOI: 10.1523/JNEUROSCI.0895-15.2016 (PMID: 26843647). (IF2015=5.924)

Mohanty S, Oruganty K, Kwon A, Byrne DP, Ferries S, Ruan Z, Hanold LE, Katiyar S, Kennedy EJ, Eyers PA and Kannan N. “Hydrophobic core variations provide a structural framework for tyrosine kinase evolution and functional specialization.” PLoS Genetics, 2016, 12: e1005885, DOI 1371/journal.pgen.1005885 (PMID: 26925779). (IF2015=6.661)

Teng Y, Bahassan A, Dong D, Hanold LE, Ren X, Kennedy EJ*, Cowell JK*. (2016)  “Targeting the WASF3-CYFIP1 Complex Using Stapled Peptides Suppresses Cancer Cell Invasion.” Cancer Research, 76(4):965-73, DOI 10.1158/0008-5472.CAN-15-1680 (PMID: 26676744). (IF2015=8.556)

Autenrieth K, Bendzunas NG, Bertinetti D, Herberg FW, Kennedy EJ.* “Defining A-Kinase Anchoring Protein (AKAP) Specificity for the Protein Kinase A Subunit RI (PKA-RI).” Chembiochem, 17: 693-7, DOI 0.1002/cbic.201500632 (PMID 26611881). (IF2015=2.850)

Gotz F, Roske Y, Schulz MS, Autenrieth K, Bertinetti D, Faelber K, Zuhlke K, Kreuchwig A, Kennedy EJ, Krause G, Daumke O, Herberg FW, Heinemann U and Klussmann E. (2016) “AKAP18:PKA-RIIa structure reveals crucial anchor points for recognition of regulatory subunits of PKA.”  J., 473(13):1881-94, DOI 10.1042/BCJ20160242 (PMID: 27102985). (IF2015=4.396

Teng Y*, Qin H, Bahassan A, Bendzunas NG, Kennedy EJ*, Cowell JK*. (2016) “The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis.” Cancer Research, 76(17): 5133-42, DOI: 10.1158/0008-5472.CAN-16-0562 (PMID: 27432794). (IF2015=8.556)

Haidar M, Ramdani G, Kennedy EJ and Langsley G. (2016) “PKA and apicomplexan parasite diseases.” Metab. Res., 48: 1-5, DOI 110.1055/s-0042-118459. (IF2015=2.029)

Goth F, Schulz MS, Autenrieth K, Bertinetti D, Faelber K, Zuhlke K, Kreuchwig A, Kennedy EJ, Krause G, Daumke O, Herberg FW, Heinemann U, Roske Y and Klussmann E.  (2016) “AKAP18:PKA-RIIa structure reveals crucial anchor points for recognition of regulatory subunits of PKA.”  Biochem. J., DOI 10.1042/BCJ20160242 (PMID: 27102985).

Mohanty S, Oruganty K, Kwon A, Byrne DP, Ferries S, Ruan Z, Hanold LE, Katiyar S, Kennedy EJ, Eyers PA and Kannan N.  (2016)  “Hydrophobic core variations provide a structural framework for tyrosine kinase evolution and functional specialization.” PLoS Genetics, 12: e1005885, DOI 10.1371/journal.pgen.1005885 (PMID: 26925779).

Bavencoffe A, Li Y, Wu Z, Yang Q, Herrera J, Kennedy EJ, Walters ET, Dessauer CW.  (2016)  “Persistent Electrical Activity in Primary Nociceptors after Spinal Cord Injury Is Maintained by Scaffolded Adenylyl Cyclase and Protein Kinase A and Is Associated with Altered Adenylyl Cyclase Regulation.”   J. Neurosci., 36(5):1660-8, DOI 10.1523/JNEUROSCI.0895-15.2016 (PMID: 26843647).

Teng Y, Bahassan A, Dong D, Hanold LE, Ren X, Kennedy EJ, Cowell JK.  (2016)  “Targeting the WASF3-CYFIP1 Complex Using Stapled Peptides Suppresses Cancer Cell Invasion.” Cancer Res., 76(4):965-73, DOI 10.1158/0008-5472.CAN-15-1680 (PMID: 26676744).

Autenrieth K, Bendzunas G, Bertinetti D, Herberg FW*, Kennedy EJ.*  (2015)  “Defining A-Kinase Anchoring Protein (AKAP) Specificity for Protein Kinase A Subunit RI (PKA-RI).”  ChemBioChem, 17(8):693-7.  DOI 10.1002/cbic.201500632 (PMID: 26611881).

Nguyen HT, Jia W, Beedle AM, Kennedy EJ, Murph MM.  (2015)  “Lysophosphatidic Acid Mediates Activating Transcription Factor 3 Expression Which Is a Target for Post-Transcriptional Silencing by miR-30c-2-3p.”  PLoS One, 10(9):e0139489, DOI 10.1371/journal.pone.0139489 (PMID: 26418018).

 Kennedy EJ* and Kannan N.  (2015)  “Dialing in EGFR signaling.” Chem. Biol., 22(6): 687-8, DOI 10.1016/j.chembiol.2015.06.001 (PMID: 26091165).

Flaherty BR, Wang Y, Trope EC, Ho TG, Muralidharan V, Kennedy EJ* and Peterson DS*.  (2015)  “The Stapled AKAP disruptor peptide STAD-2 displays antimalarial activity through a PKA-independent mechanism.” PLoS One, 10(5): e0129239, DOI 10.1371/journal.pone.0129239 (PMID: 26010880).

 Kennedy EJ and Scott JD.  (2015)  “Selective disruption of the AKAP signaling complexes.”  Methods in Molecular Biology, 1294: 137-50, DOI 10.1007/978-1-4939-2537-7_11 (PMID: 25783883).

Hermann JS, Skroblin P, Bertinetti D, Hanold LE, von der Heide EK, Wagener E-M, Zenn H-M, Klussmann E, Kennedy EJ and Herberg FW. (2015)  “Neurochondrin is an atypical RIIalpha-specific A-kinase anchoring protein.” Biochim. Biophys. Acta, 1854:1667-75, DOI 10.1016/j.bbapap.2015.04.018 (PMID: 25916936).

Mohanty S, Kennedy EJ, Herberg FW, Hui R, Taylor SS, Langsley G and Kannan N. (2015)  “Structural and evolutionary divergence of cyclic nucleotide binding domains in eukaryotic pathogens: Implications for drug design.” Biochim. Biophys. Acta, 1854:1575-85. DOI 10.1016/j.bbapap.2015.03.012. (PMID: 25847873).

Hanold LE, Watkins, CP, Liaw P, Beedle AM and Kennedy EJ. *  (2015)  “Design of a selenylsulfide-bridged EGFR dimerization arm mimic.” Bioorg. Med. Chem., 23(12):2761-6. DOI 10.1016/j.bmc.2015.03.040 (PMID: 25840798).

Hanold LE, Oruganty K, Ton NT, Beedle AM, Kannan N and Kennedy EJ. *  (2015)  “Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics.”  PLoS One, 10(3): e0118796, DOI 10.1371/journal.pone.0118796 (PMID: 25790232).

Wang Y, Ho TG, Franz E, Hermann JS, Smith FD, Hehnly H, Esseltine JL, Hanold LE, Murph MM, Bertinetti D, Scott JD, Herberg FW and Kennedy EJ. *  (2015)  “PKA-type I Selective constrained peptide disruptors of AKAP complexes.” ACS Chem. Biol., 10(6):1502-10.  DOI 10.1021/acschembio.5b00009 (PMID 25765284).

El Refaey M, Watkins CP, Kennedy EJ, Chang A, Zong Q, Ding K-H, Shi X-M, Xu J, Bollag WB, Hill WD, Johnson M, Hunter M, Hamrick MW and Isales CM.  (2015)  “Oxidation of the aromatic amino acids tryptophan and tyrosine disrupts their anabolic effects on bone marrow-derived mesenchymal stem cells.”  Mol. Cell. Endrocinol., 410:87-96. DOI 10.1016/j.mce.2015.01.034 (PMID: 25637715).

Kennedy EJ. * (2014)  “EMBO conference series: Chemical Biology 2014.” ChemBioChem. 15(18):2783-7. DOI 10.1002/cbic.201402527. (PMID: 25318996).

Fortunato MJ, Ball CE, Hollinger K, Patel NB, Modi JN, Rajasekaran V, Nonneman DJ, Ross JW, Kennedy EJ, Selsby JT, Beedle AM.  (2014)  “Development of rabbit monoclonal antibodies for detection of alpha-dystroglycan in normal and dystrophic tissue.” PLoS One, 9(5):e97567. doi: 10.1371/journal.pone.0097567 (PMID: 24824861).

Kennedy EJ. *  (2014)  “Biological Drug Products: Development and Strategies.”  Edited by Wei Wang and Manmohan Singh. ChemMedChem. 9(12): 2814-2815.

Wang Y, Ho TG, Bertinetti D, Neddermann M, Franz E, Mo GC, Schendowich LP, Sukhu A, Spelts RC, Zhang J, Herberg FW, Kennedy EJ. *  (2014)  “Isoform-selective disruption of AKAP-localized PKA using hydrocarbon stapled peptides.”  ACS Chem. Biol. 9(3):635-42. doi: 10.1021/cb400900r (PMID: 24422448).

STAFF NAVIGATION

Leave a Reply

Your email address will not be published. Required fields are marked *